Innova Biosciences introduces Biotin Check&Go! Kit
Biotin Check&Go! Kit.
Kit for confirming successful antibody-biotin conjugation.
Innova Biosciences has launched the Biotin Check&Go! Kit, which sits alongside its recently launched Conjugate Check&Go! Kit and is the company’s second lateral flow product specific to antibody labeling.
The new kit allows researchers to confirm with a quick and easy test whether an antibody has been successfully conjugated to biotin, ensuring that no materials or time are wasted using unsuccessful antibody-biotin conjugates in their downstream application.
The traditional method of biotinylation detection is the HABA assay, which is time consuming, requires large quantities of sample, and often yields variable results. Innova’s Biotin Check&Go! Kit comprises a simple immunochromatography test that requires minute quantities of antibody conjugate and is complete within 10 minutes. The new kit is compatible with Innova’s Lightning-Link® Biotinylation Kit, which allows easy and rapid conjugation of biotin to antibodies in less than 20 minutes, as well as other biotin labeling technologies available commercially.
Nick Gee, CEO and CSO at Innova Biosciences, commented: “The Lightning-Link Biotinylation Kit is one of our most popular products, and the new Biotin Check&Go! Kit has been developed following discussions with customers about their need for a quick and reliable qualitative test for biotinylation. At Innova Biosciences we are continually working with customers to ensure that the products we develop support their research, and help to increase productivity.”
Innova’s recently launched Conjugate Check&Go! Kit enables scientists to demonstrate successful conjugation of antibodies with colored labels such as fluorescent dyes and proteins, gold nanoparticles and latex beads. The Company’s conjugation technologies include Lightning-Link for antibody & protein labeling, InnovaCoat® GOLD nanoparticles and Latex beads, and Thunder-Link PLUS for oligonucleotide conjugation.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.